Browse > Article

The immunogenicity and safety of three-component DTaP vaccine in Korean infants  

Kang, Jin Han (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kim, Jong Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Jung Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Soo Young (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Hong, Young Jin (Department of Pediatrics, College of Medicine, Inha University)
Kim, Chang Hwi (Department of Pediatrics, College of Medicine, Sooncheonhyang University)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.4, 2007 , pp. 355-362 More about this Journal
Abstract
Purpose : We conducted the study to evaluate the immunogenicity and safety of three component DTaP vaccine ($Infanrix^{(R)}$) in a group of Korean healthy infants on a three-dose primary vaccination. And we compared the immunogenicity of this DTaP vaccine with two component DTaP vaccine which has been widely used in Korea. Methods : We enrolled one hundred fifty one healthy infants aged 8-9 weeks. These infants were vaccinated at age 2, 4 and 6 months of age with three component DTaP vaccine. Solicited adverse events were actively monitored for 72 hours following each vaccination, and all adverse events after each vaccination were observed for three weeks. Anti-diphtheria toxoid Ab., anti-tetanus toxoid Ab., anti-pertussis toxin Ab., anti-filamentous hemagglutinin Ab., and anti-pertactin Ab. were measured using ELISA for assessing immunogenicity of study vaccine in 60 infants. Immunogenicity analysis of two component DTaP vaccine was performed with same methods in 14 infants as control. Results : The seroconversion rates of anti-diphtheria toxoid Ab, anti-tetanus toxoid Ab. anti-filamentous hemagglutinin Ab. were 100% in both group. Seroconversion rate of anti-pertactin Ab in study group was 100%, but the rate in control group was 50%. However, geometric mean concentration of anti-pertussis toxin Ab. was higher in control group. Mild local and systemic reactions were observed within three days after vaccination, and no serious adverse events related study vaccine were happened during study period. Conclusion : Our study results suggest that three component DTaP vaccine ($Infanrix^{(R)}$) is a well-tolerable and high immunogenic vaccine, especially anti-Pertactin Ab. of the study vaccine is very immunogenic. It can be available as routine DTaP vaccination in our infants.
Keywords
Diphtheria-Tetanus-acellular Pertussis vaccines; Pertussis toxin; Filamentous hemagglutinin; Pertactin; Immunogenecity; Safety; Infant;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 1999;27:79-86   DOI   ScienceOn
2 Schmitt HJ, von Konig CHW, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41   DOI
3 Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. A randomized double blind trial comparing a two-component acellular to a whole cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12   DOI   ScienceOn
4 Olin P, Ramussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial two component, three component, and five component acellular pertussis vaccine compared with whole cell pertussis vaccine. Lancet 1997; 350:1569-77   DOI   ScienceOn
5 Edwards KM, Decker MD. Acellular pertussis vaccines for infants [editorial]. N Engl J Med 1996;334:391-2   DOI   ScienceOn
6 Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors p.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998;66:670-5
7 Liese JG, Stojanov S, Zink TH, Froeschle J, Klepadlo R, Kronwitter A, et al. Safety and immunogenicity of Biken acellualr pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 2001;20:981-8   DOI   ScienceOn
8 Hellwig SMM, van Oirschot HF, Hazenbos WI, van Spriel AB, Mooi FR, van De Winkel JGJ. Targeting to Fc gamma receptors, but not CR3(CD11b/CD18), increases clearance of Bordetella pertussis. J Infect Dis 2001;183:871-9   DOI   ScienceOn
9 de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly accinated population of the Netherlands: observation on surveillance data. Emerg Infect Dis 2000;6:348-57   DOI   ScienceOn
10 Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001;108(5);E81
11 Bernstein HH, Rothstein EP, Pichichero ME, Green JL, Reisinger KS, Blatter MM, et al. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2,4 and 6 month old infants in the United States. Vaccine 1995;13:1631-5   DOI   ScienceOn
12 Romanus V, Jonsell R, Bergquist S-O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987;6:367-71
13 Isacson J, Trollfors B, Taranger J, Zackrisson G, Laergard T. How common is whooping cough in a non-vaccinationg country? Pediatr Infect Dis J 1993;12:284-8   DOI   ScienceOn
14 Christy C, Picheichero ME, Reed GF, Decker MD, Anderson EL, Rennels MB, et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole cell pertussis vaccines. Pediatrics 1995;96:584-7
15 Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd AM, Litteer T. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in twomonth- old children. Pedatr Infect Dis J 1994;13:193-6   DOI   ScienceOn
16 Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000;182:1402-8
17 Zepp F, Knuf M, Harbermel P, Schimitt HJ, Rebsch C, Schmidtke P, et al. Pertussis specific cell mediated immunity in infants after vaccination ith a tri-component acellular pertussis vaccine. Infect Immun 1996;64:4078-84
18 Ulmer JB, Liu MA. Ethical issues for vaccines and immunization. Nat Rev Immunol 2002;2:291-6   DOI   ScienceOn
19 Decker MD, Edwards K, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines; adverse reactions. Pediatrics 1995; 96:557-66
20 Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic responses. Pediatrics 1995;96:548-57
21 Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999;67:3133-4
22 Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990;8:457-61   DOI   ScienceOn
23 Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987;9:866-83   DOI
24 Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991;78:885-9
25 Ad Hoc group for the study of pertussis vaccines. Placebo- controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988; 30:955-60
26 Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N Engl J Med 1996;334:341-8   DOI   ScienceOn
27 Zepp F, Knuf M, Habermehl P, Schmitt HJ, Meyer C, Clemens R, et al. Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand 1997; 89:307-14.
28 Halsey NA, Peter G. New developments with pertussis vaccines. Clin Immunother 1995;96:970-1
29 Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001;32:1691-7   DOI   ScienceOn
30 Njamkepo E, Rimlinger F, Thiberge S, Guiso N, Thirty five years experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002;20:1290-4   DOI   ScienceOn
31 Schmitt HJ, Schuind A, Knuf M, Zepp F, Beutel K, Wirsing von Konig CH, et al. Acellular pertussis vaccine: the rationale for an efficacy trial in Germany. J Infect Dis 1996;174 Suppl 3:S287-90   DOI
32 Liese JG, Meschievitz CK, Harzer E, Froeschle J, Hosbach P, Hoppe JE, et al. Efficacy of two component acellular pertussis vaccine in infants. Pediatr Infect Dis 1997;16: 1038-44   DOI   ScienceOn
33 Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two component acellular, a five component acellular, and a whole cell pertussis vaccine. N Engl J Med 1996;334:349-55   DOI   ScienceOn
34 Sato Y, Sato H. Developments of acellular pertussis vaccines. Biologicals 1999;27:61-9   DOI   ScienceOn
35 Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001;7(3 Suppl)526S-528   DOI   ScienceOn
36 Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000;105:e11
37 Kanai K. Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Jpn J Med Sci Biol 1980;33:107-43   DOI
38 Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Enguland JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis tetanus diphtheria vaccines. Pediatrics 2000;105:e12   DOI   ScienceOn
39 Noble GR, Bernier RH, Esber EC, Hardegree MC, Hinman AR, Klein D, et al. Acellular and whole cell pertussis vaccines in Japan. Report of a visit by US scientist. JAMA 1987;257:1351-6   DOI